Connect with us

Technology

Clearwave Joins the MEDITECH Alliance as an Accelerator Partner

Published

on

Hospitals and health systems on MEDITECH Expanse can deploy Clearwave’s AI-powered check-in, including kiosks, pre-registration, eligibility verification, payments and phone handling – with data written back into Expanse.

ATLANTA, Nov. 4, 2026 /PRNewswire/ — Clearwave, the AI Patient Engagement Platform, today announced it has joined the MEDITECH Alliance as an Accelerator Partner, formalizing a long-standing integration with MEDITECH. For MEDITECH hospitals, the partnership means a vetted path to capturing more revenue before care, lighter front desk workloads and faster, simpler patient experiences, backed by Clearwave’s continued investment in MEDITECH Expanse.

The MEDITECH Alliance is MEDITECH’s partner program for organizations with proven, successful and interoperable solutions and services. As an Accelerator Partner, Clearwave amplifies MEDITECH’s capabilities with an agentic workforce that automates the healthcare industry’s most manual work — from phone calls to health insurance checks, patient check-in and collections.

How MEDITECH Hospitals Use Clearwave for Pre-Registration and Check-In

Busy organizations already running Clearwave and MEDITECH together show the impact of this integration in action.

Holyoke Medical Center, an independent community hospital serving 17,000 patients a month, moved patient check-in, eligibility and communications onto Clearwave, with patient-entered data flowing directly into MEDITECH Expanse. The organization now sees 94% patient adoption of self-registration, average check-in times of about two minutes and a 56% co-pay collection rate, up from next to zero previously.

“A big value-driver is the data collection. It’s a strength Clearwave has that’s different than what other vendors can do with MEDITECH. The state is very pleased with what we’re able to produce, it’s better, more accurate data, flowing where we need it and it’s helped us get that much closer to being paperless,” said Chris Giroux, Director of IT Application Services at Holyoke Medical Center.

What Clearwave Automates for MEDITECH Organizations

Clearwave replaces patient engagement vendor sprawl with one AI-powered platform. Its AI agents work alongside staff across the patient journey, and every agent writes back to MEDITECH Expanse to reduce manual data entry and reconciliation.

Check-In Agent: self-service check-in kiosks, tablets and mobile modalities let patients confirm demographics, scan ID and insurance cards, sign consents and pay in under two minutesPre-Registration Agent: collects demographics, insurance, consents and payment before the visitEligibility Agent: provides real-time eligibility and benefits verification across 900+ payersPayments Agent: captures co-pays, past-due balances and card-on-file to boost collections prior to careClinical Intake Agent: ensures custom clinical questionnaires are completed and ready for providers before the visitVoice Agent: reduces hold times by instantly answering routine inquiries and offering warm transfers to human agents when necessaryOutreach Agent: automates reminders, recalls and messages that keep schedules full and no-shows low

“Hospitals can’t hire their way out of rising patient volume, and they shouldn’t have to. Our agents take on the high-volume, repetitive work across the patient journey, so MEDITECH organizations capture more revenue before care and grow access without growing administrative headcount. Joining the Alliance gives every Expanse customer a proven path to that model,” said Mike Coffey, Chief Executive Officer at Clearwave.

“We are excited to welcome Clearwave as an Accelerator in the MEDITECH Alliance,” said Brian Schuller, Director of Business Development at MEDITECH. “Collaborating through the Alliance will certainly drive enhanced operational efficiency and deliver better results for our customers.”

Learn more about Clearwave’s MEDITECH integration or schedule a demo at clearwaveinc.com.

About Clearwave

Clearwave is the AI Patient Engagement Platform designed to help healthcare organizations increase revenue and acquisition through five-star patient experiences. Eight AI agents take on time-consuming tasks with accuracy — answering every call, filling the schedule, verifying eligibility, capturing payment, checking in patients and capturing cleaner data — so staff can focus only on tasks that truly require their intervention. Backed by proven PM System and EHR integrations, healthcare organizations of all sizes achieve the lowest staff-to-patient ratios in the industry with Clearwave’s agentic workforce, all while providing the modern, simple experiences today’s patients require. Trusted by 5,000+ specialty practices and top-ranked health systems nationwide, see five-star patient reviews every day. Learn more at www.clearwaveinc.com.

About MEDITECH

MEDITECH empowers healthcare organizations to expand their vision of what’s possible with Expanse, the intelligent EHR. Expanse provides a future-ready foundation for health systems of all sizes, leveraging the power of AI, cloud computing, and advanced interoperability to support world-class care in 28 countries and territories. Boost clinician satisfaction, patient engagement, and organizational efficiency. Visit ehr.meditech.com and follow us on YouTube, LinkedIn, X, Facebook, Instagram, and Threads. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/clearwave-joins-the-meditech-alliance-as-an-accelerator-partner-302929349.html

SOURCE Clearwave, Inc.

Continue Reading

Technology

Kibow® Biotech Announces Availability of Renadyl® in Canada

Published

on

By

Expansion Brings Clinically Studied Kidney Probiotic to
More People Seeking to Maintain Kidney Health

EXTON, Pa., Nov. 19, 2026 /PRNewswire/ — Kibow Biotech, a leading innovator in probiotic dietary supplements for kidney health, today announced the availability of its flagship product, Renadyl, in Canada, marking another important milestone in the company’s mission to expand access to innovative, science-based kidney health solutions worldwide.

Developed through decades of research into the relationship between gut health and kidney function, Renadyl is a patented, clinically studied probiotic supplement scientifically formulated to help maintain healthy kidney function. Its unique approach focuses on the gut microbiome and its role in managing certain waste compounds that can place additional demands on the kidneys.

“Expanding Renadyl’s availability into Canada represents an exciting step forward in our mission to make innovative kidney health solutions accessible to more people,” said Mike Kane, President of Kibow Biotech. “Since 1997, we have been committed to advancing the science behind the gut-kidney connection and developing products that help people take a more proactive role in maintaining their kidney health. We are pleased to bring Renadyl to Canadians looking for additional ways to support their kidney health.”

Chronic Kidney Disease (CKD) affects millions of people worldwide, creating a growing need for approaches that complement traditional kidney care. Renadyl offers a gut-based approach to kidney support, using specially selected probiotic strains to help metabolize certain waste compounds in the intestinal tract and support healthy kidney function.

“As a kidney health advocate and someone who understands firsthand the challenges of living with Chronic Kidney Disease, I am excited to see Renadyl becoming available to more people around the world,” said James Fabin, founder of Dadvice TV and kidney health advocate. “People living with CKD are always looking for ways to take a more active role in their kidney health. Expanding access to products like Renadyl gives more people the opportunity to explore additional options and have informed conversations with their healthcare providers.”

Renadyl features a proprietary blend of three probiotic strains delivering 45 billion colony-forming units (CFUs) per daily serving. Designed to work within the intestinal environment, these beneficial bacteria help support the body’s natural processes for managing certain waste compounds while promoting a healthier gut environment.

The Canadian introduction builds on Kibow Biotech’s longstanding commitment to scientific research, product innovation, and education about the important relationship between gut health and kidney function.

Renadyl is now available to Canadian consumers at Renadyl.ca, where they can purchase the product and learn more about its benefits and how it works.

About Kibow Biotech, LLC
Founded October 1,1997, in Philadelphia, PA, the company’s primary mission is to offer affordable, readily available, and easily administered nutritional supplements to support kidney health and other healthcare applications. Kibow Biotech’s extensive scientific (R&D) and clinical data from multiple studies and scientific human clinical trials have been published in peer-reviewed scientific/medical journals (kibowbiotech.com/rd). The company’s flagship product, Renadyl, is marketed around the world.

Contact Information:
Michelle Adams
President
PRISM Marketing
614-989-6373
michelle@prismmarketing.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kibow-biotech-announces-availability-of-renadyl-in-canada-302945880.html

SOURCE Kibow Biotech

Continue Reading

Technology

Aptitude 8 Joins the Claude Partner Network as a Select Services Partner

Published

on

By

The recognition formalizes the Claude work Aptitude 8 has already been delivering for enterprise clients and strengthens its AI services practice.

NEW YORK, Nov. 19, 2026 /PRNewswire-PRWeb/ — Aptitude 8, a go-to-market (GTM) operations firm specializing in AI systems, today announced that it has achieved the Select partner tier in the Claude Partner Network Services Track. The tier places Aptitude 8 among the firms recognized for taking customers from pilot programs to production at scale with Claude, powered by Anthropic.

Aptitude 8’s dedicated team of certified Claude architects incorporates Claude into clients’ GTM systems and aligns the data and process it runs on. The firm is continuing to grow its certified Claude team within its AI services practice.

“AI has become essential to how businesses compete, and the companies seeing success are building it on the right foundation, wherever they’re starting from,” said Rob Guinn, CEO of Aptitude 8. “That takes deep expertise in both Claude and the data it runs on, and that combination is exactly what our team brings. Becoming a Select partner means more companies can tap into that expertise as they put Claude to work across their teams.”

Most AI initiatives stall because the system underneath them was never designed for AI. Claude fits the work Aptitude 8 already does across its clients: GTM system implementation, data architecture, systems integration, CRM engineering and portal development. Aptitude 8 architects Claude as the AI layer of a company’s GTM system and the CRM as its context layer, so Claude works from the customer’s own data and process rather than sitting beside them as a separate tool.

Aptitude 8’s Claude work spans MCP architecture that connects Claude to HubSpot and the rest of a company’s stack, custom Claude skill development, design system builds in Claude Design, and enablement and training, including Claude Code for non-developers. As usage grows, the team also helps clients manage token spend so Claude can scale with the business.

Aptitude 8’s work with Claude is already running in production for clients. For a professional services firm, Aptitude 8 turned scattered Claude usage into standardized skills, scheduled tasks and CRM workflows across sales, marketing and delivery, returning more than 1,000 hours of team capacity a year. Every proposal the firm writes now runs through Claude. For a B2B software company, Aptitude 8 built Claude Design and Claude Code workflows and a codebase agent that cut the engineering time spent triaging support requests by 80%.

To mark the announcement, Aptitude 8 is offering a free consultation; book your call at aptitude8.com/claude-services. Learn more about the Claude Partner Network at claude.com/partners.

About Aptitude 8

Aptitude 8 is a go-to-market (GTM) operations firm that architects the systems behind how businesses market, sell, and serve their customers. Deeply rooted in the HubSpot ecosystem, Aptitude 8 brings vast expertise across GTM technology and AI platforms, including Claude, to connect data, align processes, and build the infrastructure businesses need to operate more efficiently and put AI to work. The firm leads with strategy, challenges assumptions, and designs systems built to scale. Aptitude 8 makes growth operationally sound for its customers.

About the Claude Partner Network

The Claude Partner Network is how Anthropic works with the firms that put Claude into production for customers. The Services Track recognizes partners for building a certified delivery team, delivering Claude use cases for clients, and proving the work through public customer references. Partners advance through Certified, Select, Preferred, and Global Premier tiers.

Media Contact

Emily Wingrove, Aptitude 8, 1 302-428-9465, marketing@aptitude8.com, https://aptitude8.com/

View original content to download multimedia:https://www.prweb.com/releases/aptitude-8-joins-the-claude-partner-network-as-a-select-services-partner-302945796.html

SOURCE Aptitude 8

Continue Reading

Technology

Sedgwick White Paper Shows How to Separate Controllable Auto Claim Severity Drivers from Market Pressure

Published

on

By

Five-step framework and auto claim triage guide help carriers identify where claim-process friction is adding avoidable cost and delay

MEMPHIS, Tenn., Nov. 19, 2026 /PRNewswire/ — Rising auto claims severity can feel unprecedented, but Sedgwick has seen this pattern before. In the white paper, The severity you can control: A five-step framework for action, Sedgwick draws on insight from approximately 1 million auto claims every year and decades of historical claims data. Sedgwick shares what’s driving severity and what tends to happen next. Some severity is driven by market conditions. 

Overall, claim frequency has declined across several physical damage coverages, but pressure on carriers remains. Total losses are becoming more common; bodily injury severity continues to rise, and increasingly technical vehicles are changing what it takes to repair and resolve a claim. 

According to CCC Intelligent Solutions, the average paid bodily injury claim rose 10.3% year over year, and 23.1% of claims were flagged as a total loss, a record high across all loss categories. CCC also reports that advanced driver assistance systems (ADAS), sensors and cameras now trigger calibrations on nearly three in ten repairable estimates. Meanwhile, U.S. consumer price data show auto repair costs rose 60% from 2019 to 2026, nearly double the 32% rise in overall inflation. 

“Carriers don’t need more capabilities for their own sake. They need to know where a practical change will make a measurable difference. This framework gives claims leaders a way to find those opportunities and track whether they’re working,” said Chris Bakes, Managing Director, Auto Solutions at Sedgwick. “We know that some severity lives in the sheet metal and some lives in the claim process. The first can only be managed. The second can be controlled.” 

The white paper also outlines Sedgwick insights for evaluating where operational change can create the most value by applying an interactive framework developed by Sedgwick’s auto solutions experts to assess your operation and prioritize cost-containment opportunities for 2027. 

“Towing and storage is a clear example of how timing affects costs. Our towing and storage solution combines claims expertise and technology across negotiation, payment, vehicle release and transfer, helping claims teams act sooner. The result is an average bill of $1,770 versus a $2,600 industry average, a 32% reduction,” said Tim Szpila, Sr. Vice President Business Development at Sedgwick. 

The white paper also includes an auto claim triage guide that shows how information available at first notice of loss (FNOL), such as damage severity, drivability, airbag deployment and vehicle classification, can inform the likely inspection and handling path. A companion set of self-assessment questions helps carriers capture findings and identify priorities. 

The severity you can control: A five-step framework for action white paper is available at online.

About Sedgwick 
Sedgwick is the world’s leading risk and claims administration partner, helping clients thrive by navigating the unexpected. The company’s expertise, combined with the most advanced AI-enabled technology available, sets the standard for solutions in claims administration, loss adjusting, benefits administration and product recall. With over 33,000 colleagues and 10,000 clients across 80 countries, Sedgwick provides unmatched perspective, caring that counts, and solutions for the rapidly changing and complex risk landscape. Sedgwick’s majority shareholder is The Carlyle Group; Stone Point Capital LLC, Altas Partners, CDPQ, Onex and other management investors are minority shareholders. For more, see sedgwick.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sedgwick-white-paper-shows-how-to-separate-controllable-auto-claim-severity-drivers-from-market-pressure-302945902.html

SOURCE Sedgwick Claims Management Services, Inc.

Continue Reading

Trending